logo
Plus   Neg
Share
Email

Novartis Reports FDA's Priority Review For Capmatinib - Quick Facts

Novartis (NVS) said the US FDA has granted priority review to capmatinib's New Drug Application. Capmatinib is a MET inhibitor being evaluated as a treatment for first-line and previously treated patients with locally advanced or metastatic METex14 mutated non-small cell lung cancer. The company was previously granted breakthrough therapy designation for capmatinib.

Novartis noted that there are currently no approved therapies that specifically target METex14 mutated advanced NSCLC. The FDA review for Capmatinib is expected to be completed within six months.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Lowe's (LOW) is temporarily increasing wages of its employees. The latest move by the hardware retailer is to help its employees cope with the economical effects caused by the ongoing COVID-19 pandemic. The company has hiked salary by $2 per hour for all full-time, part-time, and seasonal hourly associates,... Amazon.com Inc. (AMZN) Founder and CEO Jeff Bezos is donating $100 million to food banks across the U.S. to support poor people who cannot afford food during this coronavirus crisis. Bezos made a $100 million gift to Feeding America, one of the largest U.S. nonprofit focused on food security. Feeding... Facebook on Thursday shared an update on its $100 million small-business grants program announced in March, saying that it will provide $40 million in grants to 10,000 U.S. small businesses that were impacted by the coronavirus pandemic. In March, the social media giant said it is offering $100 million in cash grants and ad credits for up to 30,000 eligible small businesses.
Follow RTT
>